BeiGene, Zai Lab Look To Clear US Delisting Uncertainties
US Exit A Viable Option?
US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.
You may also be interested in...
Delisting Looms As More US-Listed China Companies Seek To Move Closer Home
After five state-owned US-listed Chinese firms announce plans to delist from the US stock market, private firms such as Alibaba follow the lead.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits
AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.